The China Diabetes Devices Market Report is Segmented Into Device Category (Management Devices and Monitoring Devices), End User (Hospital and Clinics, Home-Care Settings, Retail Pharmacies & Diabetes Centers), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and E-Commerce / Online Pharmacies). The Market Provides the Value (in USD) and (in Units) for the Above-Mentioned Segments.

The China Diabetes Care Drugs and Devices Market is Segmented by Product Type (Devices [Monitoring Devices, and More] and Drugs [Insulin Drugs, and More]), Diabetes Type (Type 1 Diabetes and Type 2 Diabetes), Age Group (Adult, Geriatric, and More), and Distribution Channel (Offline and Online). The Market and Forecasts are Provided in Terms of Value (USD).

Market Size and Growth: The China Diabetes Devices Market is projected to grow from a value of USD 1.89 billion in 2025 to USD 3.35 billion by 2033, registering a CAGR of 9.11%. The increasing prevalence of diabetes in China, driven by factors such as urbanization, sedentary lifestyles, and unhealthy diets, is fueling the market growth. The government's emphasis on healthcare infrastructure development and insurance policies covering diabetes treatments further supports market expansion. Key Trends and Drivers: The Chinese Diabetes Devices Market is witnessing significant technological advancements, with the emergence of continuous glucose monitoring (CGM) devices and personalized insulin delivery systems. The adoption of these devices improves diabetes management efficiency, leading to better patient outcomes. Additionally, the government's initiatives to promote innovative medical technologies encourage the development and commercialization of novel diabetes devices. This, coupled with the growing awareness of diabetes prevention and management, drives the market's growth. The China diabetes devices market is a rapidly growing industry, driven by the increasing prevalence of diabetes in the country. In 2023, the market was valued at USD 12.5 billion and is expected to reach USD 19.5 billion by 2030, exhibiting a CAGR of 5.6% during the forecast period (2023-2030). This growth is attributed to factors such as the rising incidence of diabetes, increasing awareness about the disease, and technological advancements in diabetes management devices. Recent developments include: In June 2024, Novo Nordisk received approval from China's National Medical Products Administration (NMPA) for its type 2 diabetes treatment, Ozempic (semaglutide). The drug, a GLP-1 receptor agonist, has demonstrated effectiveness in controlling blood sugar levels and aiding weight loss. , In June 2023, AstraZeneca's Xigduo XR, a once-daily fixed-dose combination of the SGLT2 inhibitor dapagliflozin and metformin extended-release, was approved by China's NMPA for treating adults with type 2 diabetes. This approval offers a new therapy to address the significant unmet need for effective and convenient treatments that can help reduce complications and improve adherence in this patient population. , In November 2021, Microtech Medical Co., Ltd. received approval for its Continuous Glucose Monitoring (CGM) system device, AiDEX G7 from the National Medical Products Administration in China. This innovative device aims to enhance diabetes management by providing real-time glucose monitoring, improving patient outcomes, and facilitating better blood sugar control for individuals with diabetes. , In October 2021, EOFlow, a leading developer of wearable drug delivery systems, and Medtronic, a global leader in healthcare technology, announced a joint venture “SINOFLOW Co., Ltd.” to increase the presence of this companies in the country’s large diabetes management market, which includes various medical devices. , In May 2021, Metronom Health and Dinova Medtech formed a joint venture to launch a continuous glucose monitoring (CGM) device in China. This CGM system utilizes proprietary Opto-enzymatic technology, offering a minimally invasive alternative to traditional fingerstick meters, providing continuous glucose data with high accuracy. The device aims to enhance patient comfort and reduce infection risks, with a sensor lifespan of up to 14 days. .

The size of the China Diabetes Devices Market was valued at USD XXX Million in 2023 and is projected to reach USD XXX Million by 2032, with an expected CAGR of 4.66% during the forecast period.Diabetes devices are medical tools which can be used by people diagnosed with diabetes to manage blood sugar. It includes very important monitoring, delivery of insulin, and diabetes management as a whole.Commonly used types of diabetes devices include:Blood Glucose Meters: These are devices which determine the blood sugar levels using the analysis of a small amount of blood sample.Continuous Glucose Monitoring (CGM) Systems: These systems continue monitoring the blood sugar levels with a small sensor placed under the skin.Insulin pumps: These are devices for delivering insulin through a thin tube inserted under the skin to provide more precise insulin delivery in comparison to injections.Insulin pens: pre-filled pens that deliver a predetermined dose of insulin with an injection.The China diabetes devices market is one of the largest and fastest-growing in the world. Growing cases of diabetes, along with higher disposable incomes and better access to healthcare, have created an ever-growing demand for the devices. The Chinese government initiatives to control diabetes, especially the National Diabetes Prevention and Control Program, have accelerated growth in the market. This market is expected to continue rising due to the aging population in China and increasingly sedentary lifestyles. Recent developments include: February 2023: The MiniMed670G BLE, developed by Medtronic MiniMed, has received approval from the China NMPA. This advanced product includes an insulin pump kit, transmitter kit, and glucose sensor. It incorporates two key technologies: a hybrid closed-loop algorithm for auto mode and electrochemical impedance spectroscopy technology to monitor sensor status, ensuring accurate glucose readings., June 2022: LifeScan revealed a significant development as the peer-reviewed journal Diabetes Technology and Therapeutics (DTT) published Real World Evidence showcasing improved glycemic control in individuals with diabetes. This positive outcome is attributed to the utilization of a Bluetooth-connected Blood Glucose Meter in conjunction with a Mobile Diabetes Management Application. The OneTouch Reveal mobile app, paired with the OneTouch Verio Reflect meter via Bluetooth wireless technology, emerges as a pivotal tool supporting enhanced glycemic control for those managing diabetes.. Key drivers for this market are: Increasing Incidence of Hematologic Cancer, Growing Demand for Personalized Therapy. Potential restraints include: Unfavorable Reimbursement Scenario. Notable trends are: Monitoring Devices Market is growing with the highest CAGR in forecast period.

The China diabetes devices market, valued at $7.43 billion in 2025, is projected to experience robust growth, driven by rising diabetes prevalence, increasing awareness of effective diabetes management, and expanding access to advanced technologies. A Compound Annual Growth Rate (CAGR) of 4.66% is anticipated from 2025 to 2033, indicating a significant market expansion over the forecast period. Key growth drivers include the increasing adoption of continuous glucose monitoring (CGM) systems, offering patients real-time glucose data for better control, and the growing preference for convenient insulin delivery methods like insulin pens and pumps. Furthermore, government initiatives promoting diabetes awareness and better healthcare infrastructure contribute to the market's positive trajectory. The market is segmented into monitoring devices (self-monitoring blood glucose devices including glucometers, test strips, and lancets; and continuous glucose monitoring systems) and management devices (insulin delivery devices encompassing insulin pumps, syringes, pens, and jet injectors). While the dominance of established players like Roche, Abbott, and Medtronic is undeniable, the market also presents opportunities for smaller companies focusing on innovative technologies and cost-effective solutions catering to the diverse needs of the Chinese population. Challenges include the affordability of advanced devices, particularly in rural areas, and the need for improved patient education to maximize the benefits of available technologies. The market’s future depends on successfully addressing these challenges and continuing innovation in diabetes management technologies. The competitive landscape is characterized by both international and domestic players. International players enjoy brand recognition and advanced technology, while domestic companies benefit from lower production costs and a deeper understanding of the local market. However, both groups face challenges related to pricing strategies, regulatory hurdles, and market penetration. The market is expected to be driven by a substantial increase in the number of people with diabetes in China, along with a growing understanding of effective diabetes management among the general public. This understanding, combined with technological innovations, will continue to shape the market's future growth, paving the way for enhanced patient outcomes and a more comprehensive approach to diabetes care within China. Recent developments include: February 2023: The MiniMed670G BLE, developed by Medtronic MiniMed, has received approval from the China NMPA. This advanced product includes an insulin pump kit, transmitter kit, and glucose sensor. It incorporates two key technologies: a hybrid closed-loop algorithm for auto mode and electrochemical impedance spectroscopy technology to monitor sensor status, ensuring accurate glucose readings., June 2022: LifeScan revealed a significant development as the peer-reviewed journal Diabetes Technology and Therapeutics (DTT) published Real World Evidence showcasing improved glycemic control in individuals with diabetes. This positive outcome is attributed to the utilization of a Bluetooth-connected Blood Glucose Meter in conjunction with a Mobile Diabetes Management Application. The OneTouch Reveal mobile app, paired with the OneTouch Verio Reflect meter via Bluetooth wireless technology, emerges as a pivotal tool supporting enhanced glycemic control for those managing diabetes.. Notable trends are: Monitoring Devices Market is growing with the highest CAGR in forecast period.

China Diabetes Devices Market size was valued at USD 2.69 Billion in 2023 and is projected to reach USD 4.87 Billion by 2031, growing at a CAGR of 7.7% from 2024 to 2031.

China Diabetes Devices Market Dynamics

The key market dynamics that are shaping the China Diabetes Devices Market include:

Key Market Drivers Growing Diabetes Prevalence in China: According to the International Diabetes Federation, China has the world's largest number of adults with diabetes, with around 141.8 million affected in 2021. The National Health Commission reported an 11.2% diabetes prevalence among adults, highlighting the vital significance of enhanced diabetes care solutions.

The China Diabetes Devices report features an extensive regional analysis, identifying market penetration levels across major geographic areas. It highlights regional growth trends and opportunities, allowing businesses to tailor their market entry strategies and maximize growth in specific regions.

The China Diabetes Drugs and Devices Market size was valued at USD 12.34 Billion in 2024 and is projected to reach USD 14.10 Billion by 2032, growing at a CAGR of 1.68% from 2026 to 2032.

China Diabetes Drugs and Devices Market Drivers

Rising Prevalence of Diabetes: China is the global hub of the diabetes epidemic, with over 116 million adults affected. This surge, fueled by unhealthy diets, sedentary lifestyles, and urbanization, is boosting demand for diabetes drugs and monitoring devices. This presents a significant opportunity for pharmaceutical companies and device manufacturers, leading to increased government and private investments in diabetes care solutions.

Aging Population and Increasing Life Expectancy: China's aging population is driving a rise in chronic diseases, including diabetes, primarily affecting older individuals. The National Health Commission reports a sharp increase in diabetes incidence among those over 60, emphasizing the need for advanced treatments and monitoring tools. The combination of an aging population and longer life expectancy leads to a sustained demand for diabetes management solutions, including insulin therapy and glucose monitoring devices.

Government Healthcare Reforms and Policy Support: The Chinese government has implemented policies to enhance healthcare access, notably affecting the diabetes drugs and devices market. The National Health Commission has integrated diabetes care into the healthcare system, offering more affordable treatments. The inclusion of diabetes drugs in the National Reimbursement Drug List has reduced patient costs. Government support for the Affordable Healthcare for All initiative and health insurance coverage for diabetes management is also driving market growth by promoting broader access to essential treatments and devices.

In 2019, the market size of self-monitoring blood glucose (SMBG) devices in China was estimated at 1.3 billion yuan. The monitoring and control of blood glucose level are crucial for patients suffering from diabetes. There is no cure so far for this potentially fatal disease. Yet, it can be effectively managed through education, adoption of healthy lifestyles with different medications and blood glucose testing equipment.

Why is SMBG important to diabetes patients?

Diabetes is a long-term disease that occurs when the pancreas fails to produce any or enough insulin, or when the body does not use the insulin it produces properly. Self-monitoring blood glucose devices support the maintenance of blood glucose at the desired levels, in which hypoglycemia (low blood sugar levels) or hyperglycemia (high blood sugar levels) can be detected and prevented. In China, blood glucose monitoring is a multibillion-yuan-worth business which consists of two segments: glucometer devices and disposable consumables (lancet and test strips). The latter is the main revenue driver.

The market outlook of diabetes management

Beijing has launched various healthcare programs and reforms to strengthen diabetes-related care. Under the current regulation, local governments are obliged to provide a free medical check-up per year to citizens aged over 65 years. According to “Healthy China 2030” - the national health plan launched in 2016 - the diabetes awareness rate would be increased to 50 percent by 2022, a significant increment compared to the level in 2019. The overall goal is to raise the standard management rate of diabetes to over 70 percent by 2030. Alongside positive changes in policy and regulatory environment, technological advancements have been thriving in the diabetes care market. One example is the collaboration of the Danish drugmaker Novo Nordisk and the Chinese medical consulting platform WeDoctor to offer doctors and patients to stay in touch through a user-friendly mobile app.

The size of the China Continuous Glucose Monitoring Devices Market was valued at USD 505.13 Million in 2023 and is projected to reach USD 1009.05 Million by 2032, with an expected CAGR of 10.39% during the forecast period. The China continuous glucose monitoring (CGM) devices market is expanding at a fast pace because of growing cases of diabetes and technological developments. CGM is applied for the continuous tracing of glucose level for diabetic people, which shows considerably more effective result compared to standard approaches that employ intermittent glucose measurements. These devices are of great importance more so inevaluation of complication in diabetic patients since they give trends and patterns of glucose level. It due to increasing concerns for health, advancement in technology and policies framed by governments for treatment of diabetes. Some of the trends include advancements in accurate, easy to use and cost effective CGM devices with compatibility to mobile health applications for enhanced patient interaction and insight into the data. Recent developments include: November 2023: SIBIONICS, a Chinese company, announced that it received the CE Mark for its revolutionary GS1 CGM. This significant milestone marks a momentous achievement for SIBIONICS, facilitating the distribution and utilization of this game-changing technology throughout the European market., June 2023: Medical diagnostic company Know Labs is aiming to release the world’s first commercially available non-invasive glucose monitor with the launch of its Generation (Gen) 1 device. The device houses the company’s Bio-RFID technology, which was shown to consistently and accurately measure glucose levels non-invasively in a feasibility study conducted by the Washington, US-based company across late 2022 and early 2023.. Key drivers for this market are: Rapidly Increasing Incidence and Prevalence of Diabetes, Technological Advancements in the Market. Potential restraints include: Monopolized Supply Chain and High Cost of Devices. Notable trends are: Rising Diabetes Prevalence in China.

The China Continuous Glucose Monitoring (CGM) Devices market is experiencing robust growth, projected to reach a market size of $505.13 million in 2025 and maintain a Compound Annual Growth Rate (CAGR) of 10.39% from 2025 to 2033. This expansion is fueled by several key factors. Firstly, the rising prevalence of diabetes in China, coupled with increasing awareness of the benefits of CGM technology for improved blood sugar management and reduced complications, is driving significant demand. Secondly, advancements in CGM technology, including smaller, more user-friendly devices with improved accuracy and longer battery life, are making them more accessible and appealing to patients. Government initiatives promoting better diabetes care and the expansion of healthcare infrastructure further contribute to market growth. Competition is intense, with key players such as Abbott Diabetes Care, Dexcom Inc., and Medtronic PLC holding significant market share, but also facing challenges from emerging domestic companies like Yuwell and Jiunuo Medical. The market segmentation shows a strong demand for both sensor and durable components of CGM systems. Future growth will likely depend on continued technological innovation, pricing strategies that improve affordability, and successful partnerships between manufacturers and healthcare providers to improve patient access and education. The continued high CAGR suggests substantial growth potential in the coming years. While challenges remain, such as the need for increased affordability and healthcare system integration, the long-term outlook for the China CGM market remains positive. The focus will be on expanding market penetration among the large diabetic population, particularly in underserved regions, and increasing the adoption of CGM technology within the Chinese healthcare system. The success of domestic companies will significantly influence the overall market dynamics. The market segmentation, with a focus on both sensor and durable components, indicates opportunities for specialized manufacturers and further innovation within these segments. Recent developments include: November 2023: SIBIONICS, a Chinese company, announced that it received the CE Mark for its revolutionary GS1 CGM. This significant milestone marks a momentous achievement for SIBIONICS, facilitating the distribution and utilization of this game-changing technology throughout the European market., June 2023: Medical diagnostic company Know Labs is aiming to release the world’s first commercially available non-invasive glucose monitor with the launch of its Generation (Gen) 1 device. The device houses the company’s Bio-RFID technology, which was shown to consistently and accurately measure glucose levels non-invasively in a feasibility study conducted by the Washington, US-based company across late 2022 and early 2023.. Notable trends are: Rising Diabetes Prevalence in China.

The size of the China Insulin Drugs And Delivery Devices market was valued at USD XXX Million in 2023 and is projected to reach USD XXX Million by 2032, with an expected CAGR of 2.60% during the forecast period.Insulin drugs and delivery devices are crucial in managing a chronic condition where the blood sugar levels are high. These insulin drugs are administered to control the blood glucose levels, as they mimic the natural ones that the body produces. There are various forms in which insulin drugs come, such as in insulin pens, vials, and prefilled syringes.Insulin delivery devices have been designed to accurately and conveniently administer insulin. For instance, insulin pens are small portable devices that offer detailed dosing; making injections self-manageable. The more complex devices involve insulin pumps, which provide a continuous or bolus dose of insulin to manage blood sugar much better.The Chinese market for insulin drugs and delivery devices is one of the largest, but also one of the speediest-growing in the world. Aging population coupled with high rates of diabetes has fueled demand for these products in the country. The extensive healthcare infrastructure and advanced medical technology across the country have also played a role in driving the growth of this market. The rise in need for diabetes management will increase the growth curve for the Chinese market for insulin drugs and delivery devices. Recent developments include: October 2022: Novo Nordisk announced headline results from the ONWARDS 5 phase 3a trial with once-weekly insulin icodec in people with type 2 diabetes. The ONWARDS 5 trial was a 52-week, open-label efficacy and safety treat-to-target trial investigating once-weekly insulin versus once-daily basal insulin (insulin degludec or insulin glargine U100/U300)., July 2022: Gan & Lee Pharmaceuticals Co., Ltd. announced that China's National Medical Products Administration (NMPA) cleared its investigational new drug application for GZR4 to improve the management of diabetes. GZR4, a new generation of once-weekly ultra-long-acting insulin, is expected to be dosed once a week by subcutaneous injection in humans to achieve smooth control of basal blood glucose for one week.. Key drivers for this market are: , The Rise in Global Prevalence of Cases of Obesity due to Modern Sedentary Lifestyles; Rise in Awareness and Disposable Income in Developed Economies. Potential restraints include: , Highly Cost of Branded Products in Emerging Countries; Severe Adverse Associated with Medication Including Seizures, Suicidal Attempts and Even Death; Adoption of Traditional Yoga and Herbal Products. Notable trends are: Rising diabetes prevalence.

The China Diabetes Drugs and Devices market report offers a thorough competitive analysis, mapping key players’ strategies, market share, and business models. It provides insights into competitor dynamics, helping companies align their strategies with the current market landscape and future trends.

The global diabetes care devices market is expected to reach USD 64.5 billion in 2024. The sales are expected to grow even higher and will be estimated at USD 117.7 billion in 2034 due to the rising diabetes population. The diabetes care devices market is anticipated to record a CAGR of 6.2% between 2024 and 2034.

Attributes	Description
Estimated Global Diabetes Care Devices Market Size (2024E)	USD 64.5 billion
Projected Global Diabetes Care Devices Market Value (2034F)	USD 117.7 billion
Value-based CAGR (2024 to 2034)	6.2%

Semi-annual Industry Update

Particular	Value CAGR
H1	5.7% (2023 to 2033)
H2	5.2% (2023 to 2033)
H1	4.5% (2024 to 2034)
H2	4.2% (2024 to 2034)

Country-wise Insights

Countries	CAGR 2024 to 2034
India	8.8%
China	8.4%
South Korea	8.1%
Australia	6.7%
France	4.3%
United States	3.4%

Category-wise Insights

Segment	Glucose Monitoring Devices (Product Type)
Value Share (2024)	58.3%

Segment	Diabetes Type II (Indication)
Value Share (2024)	19.7%

Diabetes Devices Market Outlook

The global diabetes devices market size is expected to grow from USD 26.8 billion in 2023 to USD 48.7 billion by 2032, exhibiting a compound annual growth rate (CAGR) of 6.7% during the forecast period. This market growth is primarily driven by the increasing prevalence of diabetes worldwide, coupled with technological advancements in diabetes management devices. Factors such as the growing geriatric population, rising awareness about diabetes management, and increasing healthcare expenditures are contributing to the robust expansion of the diabetes devices market.

One of the significant growth factors for the diabetes devices market is the rising incidence of diabetes globally. According to the International Diabetes Federation, the number of people living with diabetes is expected to rise from 463 million in 2019 to 700 million by 2045. This alarming increase in diabetes prevalence is spurring a demand for effective management devices, thereby driving market growth. Additionally, lifestyle changes, urbanization, and unhealthy eating habits are major contributors to the rise in diabetes cases, further augmenting the market's expansion.

Technological advancements in diabetes management devices are another critical driver of market growth. Innovations such as continuous glucose monitoring (CGM) systems, smart insulin pens, and artificial pancreas systems are revolutionizing diabetes care. These advanced devices provide real-time glucose monitoring, accurate insulin delivery, and improved patient outcomes. The integration of digital health technologies, such as mobile applications and cloud-based data storage, is enhancing patient engagement and adherence to diabetes management plans, thus fueling market growth.

The increasing adoption of home-based diabetes management devices is also contributing to the market's expansion. The convenience and ease of use provided by homecare devices are encouraging more patients to monitor and manage their diabetes at home. This trend is especially prominent among the elderly population, who may find it challenging to visit healthcare facilities frequently. Homecare diabetes devices, such as blood glucose meters and insulin delivery devices, are gaining popularity due to their user-friendly features and cost-effectiveness, thereby driving market growth.

Regionally, North America holds a significant share of the diabetes devices market, attributed to the high prevalence of diabetes, well-established healthcare infrastructure, and increasing healthcare expenditure. The Asia Pacific region is expected to witness the fastest growth during the forecast period, driven by the rising diabetes population, improving healthcare facilities, and increasing awareness about diabetes management. Countries such as China and India are major contributors to the regional market's growth, owing to their large diabetic populations and government initiatives to improve diabetes care.

Product Type Analysis

The diabetes devices market is segmented based on product type, including blood glucose meters, continuous glucose monitoring (CGM) devices, insulin delivery devices, lancets, and others. Blood glucose meters are among the most commonly used devices for diabetes management. These devices are essential for monitoring blood glucose levels and provide immediate feedback to patients, enabling them to manage their condition effectively. The demand for blood glucose meters is driven by their affordability, ease of use, and increasing diabetes prevalence.

Continuous glucose monitoring (CGM) devices are gaining significant traction in the diabetes devices market. CGM systems provide real-time glucose readings, allowing continuous monitoring of glucose levels without the need for frequent finger pricks. These devices are particularly beneficial for patients with type 1 diabetes and those with unstable glucose levels. The increasing adoption of CGM systems is driven by their ability to provide comprehensive glucose profiles, improving glycemic control and reducing the risk of diabetes-related complications.

Insulin delivery devices, including insulin pens, insulin pumps, and insulin syringes, are crucial for diabetes management, especially for patients with type 1 diabetes and insulin-dependent type 2 diabetes. Insulin pens and pumps offer precise insulin dosing, enhancing patient compliance and glycemic control. The development of smart insulin pens with connectivity features and integration with mobile applications is further driving the adoption of insulin delivery devices

In 2020, the market size of blood glucose monitoring systems in China was valued at 8.5 billion yuan. Blood glucose monitoring is essential in the treatment and care of diabetes patients. Driven by the rising diabetes number in the world's most populous country, the Chinese market for blood glucose monitoring was expected to grow by a double-digit in the next few years.

Global Diabetes Care Devices market size was USD 10.26 Billion in 2022 and it is forecasted to reach USD 18.69 Billion by 2030. Diabetes Care Devices Industry's Compound Annual Growth Rate will be 8.76% from 2023 to 2030. Market Dynamics of the Diabetes Care Devices Market

Drivers of the diabetes care device market:

The demand for monitoring and treatment devices is being fuelled by an increase in diabetes prevalence worldwide

Diabetes is becoming more common everywhere, but notably in developing nations like China and India. The prevalence of diabetes is fast increasing, and this is due to a number of causes, including growing urbanisation and an increase in sedentary lifestyle, particularly in developing nations. According to the International Diabetes Federation, there were 425 million adult diabetics worldwide in 2017, and by 2045, that number is expected to reach 630 million. These studies suggest that between 55 and 60 percent of people worldwide have diabetes, with the majority living in China, India, United States, Brazil, and Mexico. Currently, China and India make up about half of the world's diabetic population.

Restraining Factor of the diabetic device care market:

Diabetes care devices tend to be quite expensive and challenging to use

The glucose testing machine is high in price and uncomfortable to use. Diabetes care devices outcomes are not always precise. Additionally, a few things prevent the market from growing. This includes uncomfortable sensor insertions on the body. Additionally, the diabetes care devices cause skin rashes, adhesion problems.

Impact of the COVID-19 pandemic on the Diabetes Care Devices Market: COVID-19 increased the market growth for diabetic care equipment. This is due to the fact that patients with COVID-19 infections were seen to have elevated blood sugar levels. Due to the rising prevalence of diabetes and the expanding market, various firms have introduced innovative, cutting-edge diabetes care devices in the post-pandemic era. One of the biggest global health crises of the twenty-first century is diabetes. This illness, which can cause life-altering problems, is being lived with by an increasing number of people each year. In addition to more than millions adults with impaired glucose tolerance who are at a high risk of getting diabetes in the future, there are an estimated more than half of million adults with diabetes worldwide. With rising obesity rates, shifting food preferences, and an ageing population, diabetes incidence and prevalence are on the rise. Therefore, there is a sizable market potential in the global diabetes care devices & pharmaceuticals market given the enormous numbers of diabetics globally and the enormous financial implications connected with diabetes and linked subsequent health issues.

The China insulin drugs and delivery devices market presents a significant opportunity, with a 2025 market size of $6.20 billion and a projected CAGR of 2.60% from 2025 to 2033. This growth is driven by the rising prevalence of diabetes, an aging population, and increasing awareness of effective diabetes management. The market is segmented into various insulin drug types, including basal/long-acting, bolus/fast-acting, traditional human insulins, combination insulins, and biosimilars. The devices segment comprises insulin pumps, pens, syringes, and jet injectors. Novo Nordisk, Sanofi, and Eli Lilly are major players in the insulin drug market, while Medtronic and Ypsomed lead in the delivery devices sector. Competition is intense, with biosimilar entrants challenging established brands, and continuous innovation in delivery systems aiming for improved patient convenience and efficacy. While market growth is projected, challenges remain, including affordability concerns, particularly for newer, more advanced technologies. The market's future growth hinges on government initiatives to improve healthcare access, continued technological advancements in insulin delivery, and the successful launch and adoption of newer insulin formulations. The increasing adoption of insulin pumps and pens, driven by patient preference for convenience and improved glycemic control, fuels the devices segment's growth. However, the high cost of these advanced devices restricts access for a significant portion of the population. The market will likely see increased focus on affordable biosimilars to improve accessibility while maintaining quality treatment. The Chinese government's initiatives to strengthen its healthcare system, including national diabetes prevention and management programs, are expected to play a crucial role in shaping the market trajectory over the forecast period. Furthermore, the emergence of innovative insulin delivery technologies, such as smart insulin pens and closed-loop systems, will likely impact market dynamics. Future market trends will depend on the successful integration of these technologies and their accessibility to the broader Chinese population. Recent developments include: October 2022: Novo Nordisk announced headline results from the ONWARDS 5 phase 3a trial with once-weekly insulin icodec in people with type 2 diabetes. The ONWARDS 5 trial was a 52-week, open-label efficacy and safety treat-to-target trial investigating once-weekly insulin versus once-daily basal insulin (insulin degludec or insulin glargine U100/U300)., July 2022: Gan & Lee Pharmaceuticals Co., Ltd. announced that China's National Medical Products Administration (NMPA) cleared its investigational new drug application for GZR4 to improve the management of diabetes. GZR4, a new generation of once-weekly ultra-long-acting insulin, is expected to be dosed once a week by subcutaneous injection in humans to achieve smooth control of basal blood glucose for one week.. Notable trends are: Rising diabetes prevalence.

The size of the China Self-Monitoring Blood Glucose Devices Market was valued at USD 1.30 Million in 2023 and is projected to reach USD 1.98 Million by 2032, with an expected CAGR of 6.20% during the forecast period. Self-monitoring blood glucose devices gradually became one of the most essential tools for patients diagnosed with diabetes. This is simply because they offer the patient a chance to control the condition. They measure the blood sugar level. This will allow the patients to make decisions on their diet, exercise, or medication. Coupled with the staggering rate at which diabetes has risen in China, the market for SMBG devices also increases incrementally. Increased awareness about diabetes and its complications have spurred more demand for such products. The increasing number of patient pool diagnosed with diabetes fuels the demand for monitoring devices to control the blood sugar levels. Moreover, in the past two years, the complexity of SMBG technology has decreased and more accurate, user-friendly, and affordable devices are being designed, which will further fuel this market. The Chinese government also provides excellent support for the development of the SMBG devices market. The government has undertaken several measures to motivate domestic producers to develop quality and affordable devices as well as to raise awareness about diabetes and its relevance for self-monitoring. Recent developments include: December, 2023: Sinocare Inc. set up offline after-sales service outlets, to explore new thinking of preventing and controlling chronic diseases in China. In addition to offline free detection and maintenance services provided to the users with Sinocare Blood Glucose Meter, as well as chronic disease detection for the blood glucose meter users and the masses nearby on the scene, it will also carry out patient education activities regularly, to improve the management awareness of surrounding residents in chronic disease., November, 2022: Roche featured two new glucose meter products, ACCU-CHEK Instant Glucometer and ACCU-CHEK Guide Me Glucometer, and a new digital diabetes management platform at the China International Import Expo to highlight integrated solutions from Roche Pharmaceuticals and Roche Diagnostics. The two glucometers exhibited by Roche Diagnostics are both newly launched in 2022 in China, which can measure blood glucose in a user-friendly way, with measurement accuracy.. Key drivers for this market are: Rising Prevalence of Cancer Worldwide, Technological Advancements in Diagnostic Testing; Increasing Demand for Point-of-care Treatment. Potential restraints include: High Cost of Molecular Diagnostic Tests, Lack of Skilled Workforce and Stringent Regulatory Framework. Notable trends are: Rising Diabetes Prevalence in China.

Diabetes Devices Market Outlook

According to our latest research, the global diabetes devices market size reached USD 34.7 billion in 2024, reflecting robust demand driven by the rising prevalence of diabetes and technological advancements in monitoring and management devices. The market is projected to grow at a CAGR of 7.1% from 2025 to 2033, reaching approximately USD 64.9 billion by 2033. This strong growth trajectory is primarily fueled by increasing awareness about diabetes management, the advent of innovative device technologies, and expanding healthcare infrastructure globally.

One of the primary growth factors for the diabetes devices market is the escalating global burden of diabetes, particularly type 2 diabetes, which has reached epidemic proportions in both developed and developing economies. The World Health Organization estimates that over 537 million adults are living with diabetes worldwide, and this figure is expected to rise steadily in the coming years. The increasing incidence of obesity, sedentary lifestyles, and unhealthy dietary habits have significantly contributed to the surge in diabetes cases, creating an urgent need for effective monitoring and management solutions. As a result, demand for blood glucose monitoring devices, insulin delivery systems, and continuous glucose monitoring (CGM) devices has surged, driving the expansion of the market.

Technological innovation remains a key catalyst in the diabetes devices market, with manufacturers focusing on enhancing the accuracy, convenience, and connectivity of their products. The integration of digital technologies such as wireless connectivity, cloud-based data storage, and mobile health applications has revolutionized diabetes management, allowing patients and healthcare providers to monitor glucose levels and insulin usage in real-time. Continuous glucose monitoring systems, in particular, have seen rapid adoption due to their ability to provide continuous, real-time data, reduce the frequency of fingerstick testing, and improve glycemic control. These advancements not only improve patient outcomes but also enhance the user experience, further propelling market growth.

In addition to technological progress, favorable reimbursement policies and increasing investments in healthcare infrastructure have played a pivotal role in expanding access to diabetes devices, especially in emerging markets. Governments and private insurers are increasingly recognizing the long-term cost benefits of early diabetes detection and management, leading to broader coverage for advanced devices. Furthermore, the rise of home healthcare and telemedicine has enabled patients to manage their condition more effectively outside traditional clinical settings. This shift towards decentralized care is expected to sustain the growth momentum of the diabetes devices market over the forecast period.

From a regional perspective, North America currently dominates the global diabetes devices market, accounting for the largest revenue share in 2024, followed closely by Europe and Asia Pacific. The high prevalence of diabetes, well-established healthcare infrastructure, and early adoption of advanced technologies in the United States and Canada have contributed to the region's leadership. Meanwhile, Asia Pacific is emerging as a high-growth region, driven by rising diabetes incidence in populous countries like China and India, increasing healthcare expenditure, and expanding awareness about diabetes management. Europe also maintains a significant market presence due to supportive government initiatives and a strong focus on research and development. Latin America and the Middle East & Africa are expected to witness steady growth, albeit from a smaller base, as access to healthcare improves and awareness campaigns gain traction.

Product Type Analysis

The product type segment of the diabetes devices market is broadly categorized into blood glucose monitoring devices, insulin